M Protein and Plasma Cell Disorders

Introduction to M Protein

The National Comprehensive Cancer Network recommends that M protein represents the presence of a monoclonal immunoglobulin produced by an abnormal clone of plasma cells, which can indicate various conditions ranging from benign monoclonal gammopathy of undetermined significance (MGUS) to malignant multiple myeloma (MM) 1, 2

M proteins can be complete immunoglobulins (IgG, IgA, IgM, IgD, or IgE) or fragments such as free light chains (kappa or lambda) 2
Detection methods include serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (SIFE), serum free light chain (FLC) assay, urine protein electrophoresis (UPEP), and immunofixation (UIFE) 2

The National Comprehensive Cancer Network states that M proteins can indicate various plasma cell disorders including monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, Waldenström macroglobulinemia, light chain amyloidosis, and solitary plasmacytoma 1, 2, 3
The presence of M protein is a key diagnostic marker for plasma cell disorders, with the type, concentration, and behavior of M protein over time helping to determine prognosis 2, 3

The International Myeloma Society recommends that monitoring M protein levels is crucial for assessing disease progression and response to treatment 2
In MGUS, risk factors for progression to malignancy include non-IgG isotype, M protein concentration ≥1.5 g/dL, and abnormal serum free light chain ratio 3, 4

M proteins can cause organ damage through direct tissue deposition, autoantibody activity, and hyperviscosity syndrome 5, 6, 7
Specific M protein-related conditions include neurological disorders, renal disorders, hematological disorders, and POEMS syndrome 6, 7

The National Comprehensive Cancer Network recommends that detection of M protein requires comprehensive evaluation to determine its clinical significance, and regular monitoring of M protein levels is essential for patients with MGUS to detect progression to malignancy 2, 3
Treatment decisions are based on the underlying disorder, M protein levels, and presence of end-organ damage, with risk stratification guiding follow-up frequency 2, 3, 4, 7